ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Trauma, Traumatic Injury, Traumatic Brain Injury, Wounds and Injuries, Penetrating Injury, Blunt Injury, Major Trauma, Multiple Trauma

In brief

The EPO-TRAUMA study is a prospective, multi-centre, double-blind, phase III, randomised controlled trial evaluating the efficacy of epoetin alfa compared to placebo in reducing mortality and severe disability at six months in critically ill trauma patients. 2500 mechanically ventilated ICU patients admitted with a primary trauma diagnosis presenting to the ICU will be recruited into the study from participating study centres in Australia, New Zealand, Europe, and Saudi Arabia.

Key facts

Study ID
NCT04588311
Run by
Australian and New Zealand Intensive Care Research Centre
People needed
2500
Starts
2020-11-09
Expected to finish
2027-08-31
Last updated by the study team
2025-07-16

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.